SCHAUMBURG, Ill.--(BUSINESS WIRE)--APP Pharmaceuticals, Inc. (Nasdaq:APPX), a leading manufacturer of multi-source and branded injectable pharmaceutical products, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Irinotecan Hydrochloride Injection, 40 mg/2mL and 100mg/5mL, the generic equivalent of Camptosar® Injection manufactured by Pfizer Inc. APP has immediately commenced marketing and shipping the product. APP’s irinotecan is AP-rated, bar-coded and latex-free. According to IMS data, sales of Camptosar® in the United States were approximately $556 million in 2007.
